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responsive than p53-deficient GBM-SCs. Here we found that 
either forkhead box O (FoxO) proteins or non-functional p53 
maintain stemness and survival of primary GBM-SCs after 
combination treatment with gamma-IR and dual PI3K/mTOR 
inhibitors. 
 
Material and Methods: Patient-derived GBM-SCs were 
cultured under stem cell culture conditions. Western blot was 
used for protein expression analyses. Sphere formation 
served as a surrogate assay for self-renewal and cell death 
was assessed flow cytometrically. Lentiviral RNA-knockdowns 
or overexpression of p53 and FoxO proteins were employed 
for molecular studies. ChiP assay was used to assess binding 
of FoxO transcription factors to the regulatory region of the 
sox2 gene. 
 
Results: p53-proficient GBM-SCs lost stem cell markers and 
self-renewal ability and underwent differentiation a few days 
after the combination treatment with γIR and a PI3K/mTOR 
inhibitor (PI-103 or NVP-BEZ235); expression of FoxO proteins 
was also lost. In contrast, stem cell markers and FoxO 
proteins were not lost anymore upon p53 shRNA knockdown 
or in p53-deficient GBM-SCs. FoxO1/3 knockdown also caused 
reduced sphere formation and cell survival after the 
combination treatment in p53-proficient but not in p53-
deficient GBM-SCs. Furthermore, FoxO1 and FoxO3 were 
found to bind to the sox2 regulatory region in GBM-SCs, and 
combined FoxO1/3 deletion abolished Sox2 expression which 
was confirmed with a novel synthetic FoxO1 inhibitor. 
Finally, FoxO overexpression prevented GBM-SC 
differentiation upon combination treatment with gamma-IR 
and dual PI3K/mTOR inhibitors. 
 
Conclusion: Our results suggest that FoxO proteins are 
crucial for functional stemness and survival in p53-proficient 
GBM-SCs and that non-functional p53 can maintain these 
functions instead. 
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Purpose or Objective: Tumour recurrence in glioblastoma 
(GBM) patients is inevitable despite multi-modality treatment 
with surgery, radiotherapy and chemotherapy. Tumour 
recurrence is thought to be driven by a small population of 
glioblastoma stem-like cells (GSCs) that are resistant to 
conventional therapies. DNA damage response (DDR) 
signalling has been shown to be up-regulated in GSCs and 
implicated in radioresistance and treatment failure. However 
the cause of enhanced DDR signalling in GSCs and its 
contribution to radiation resistance and tumour recurrence is 
not well understood. The objectives of this study were to 
investigate the underlying cause of DDR upregulation and 
treatment resistance in GSCs and to identify novel 
therapeutic targets. 
 
Material and Methods: A panel of primary GBM cell lines 
cultured under conditions to enrich for or deplete the tumour 
stem cell population (GSC vs bulk respectively) were utilised 
to investigate enhanced GSC DDR under basal conditions and 
after ionising radiation. Confirmatory studies were performed 
in cells sorted for the putative GSC marker CD133. The 
effects of a panel of small molecule DDR inhibitors on cell 
survival in GSC and bulk cells were explored. 
 
Results: GSCs exhibited higher levels of total and activated 
DDR targets ATR, CHK1, ATM and PARP1 under basal 
conditions and were radioresistant compared to paired bulk 
populations. Augmented DDR in GSCs has been linked to 
increased reactive oxygen species levels by other authors, 
however we were unable to demonstrate this in our GSC 
cultures. Instead, we show that RPA is significantly higher in 
replicating GSCs and confirm by DNA fibre assays that GSCs 
and CD133+ cells have increased numbers of stalled 
replication forks, fewer new origins and slower DNA 
replication compared to bulk or CD133- populations, 
suggesting that replication stress may be important to 
constitutive DDR activation seen in GSCs. Importantly, 
inhibition of ATR or CHK1 was cytotoxic to GSCs and when 
combined with PARP inhibition caused DNA double strand 
breaks and reduced neurosphere formation.  
 
Conclusion: This study demonstrates that replication stress is 
a hallmark of GSCs. We implicate replication stress in GSCs as 
the driver of enhanced DDR and radioresistance in GSCs and 
therefore a cause of tumour recurrence in GBM. This suggests 
that replication stress is a GSC specific therapeutic target, 
and we are able to demonstrate the effectiveness of 
inhibitors of replication stress response in targeting this 
treatment resistant tumour subpopulation. 
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Purpose or Objective: Although prostate cancer is the most 
common malignancy in men, the cellular and molecular 
mechanisms underlying tumor progression and therapy 
resistance remain poorly understood. Within this study we 
discovered cancer stem cell (CSC)-related properties, CSC 
plasticity and tumor heterogeneity as a source for 
radiotherapy resistance. Therefore, analysis of CSC-based 
biomarkers might be an important predictive tool for 
individualized radiotherapy and treatment. 
 
Material and Methods: Global gene expression and 
membrane proteomic profiling of radioresistant sublines from 
established prostate cancer cell lines identified novel 
biomarker for prostate cancer radioresistance, which were 
validated in NMRI nu/nu mice in vivo, with 
immunohistochemical analysis of tumor sections and in short-
term ex vivo cultures of primary prostate cancer tissue. 
 
Results: Within this study we found that the aldehyde 
dehydrogenase (ALDH) activity is a predictive marker of a 
radioresistant prostate cancer progenitor population with 
enhanced DNA repair capacity and activation of epithelial-
mesenchymal transition (EMT). The activation of the WNT/β-
catenin signaling pathway was identified as a key molecular 
mechanism, which link CSC-related properties to 
radioresistance. We found that the β-catenin/TCF 
transcriptional complex is directly activating the ALDH1A1 
gene transcription, and molecular targeting of the WNT 
pathway with XAV939 leads to radiosensitization. Moreover, 
our study revealed that irradiation causes long-term up-
regulation of stem cell markers and induces tumor cell 
reprogramming. This phenotypic plasticity is associated with 
genetic and epigenetic changes induced by irradiation, such 
as the histone H3 methylation within the promotor sequence 
of the ALDH1A1 gene. The inhibition of histone methylation 
by DZNep triggered radiosensitization by apoptosis induction 
in vitro and in vivo. 
 
Conclusion: Our findings suggest that ALDH-positive CSCs 
contribute to tumor radioresistance, but these radioresistant 
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properties are dynamic in nature. Therapeutic agents 
inhibiting tumor cell reprogramming may have the potential 
to increase the effectiveness of radiotherapy. Moreover, 
monitoring of CSC-related biomarker before and during the 
course of radiotherapy may be able to predict therapy 
response and clinical outcome. 
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Purpose or Objective: This study analyzed whether short-
term death of patients with peripheral stage I NSCLC can be 
predicted reliably to select a sub-group of patients, which 
will not have a benefit from SBRT and which can be referred 
to wait and see. 
 
Material and Methods: 802 patients with early stage NSCLC 
treated with SBRT in 5 institutes for whom information on 
overall survival within the first six months after treatment 
was available were included in this analysis. The probability 
of dying within six months after treatment was modeled by 
multivariate logistic regression; this interval was chosen 
because death of early stage NSCLC is a rare event within six 
months after diagnosis. Model fitting was performed using the 
LASSO method which simultaneously serves to select the 
features most closely related to the outcome. The 
performance of the model that would be achieved on an 
independent dataset was estimated using double 10-fold 
cross validation (CV). Because with CV the estimation of test 
performance depends somewhat on the splitting of the data 
sets, double 10-fold CV was repeated 100 times, resulting in 
1000 models from which the variance in the performance 
measure could be obtained. The variables age, gender, ECOG 
status, operability, FEV1 and Charlson comorbidity index 
(CCI) where considered for model building. 
 
Results: Using different variable combinations for model 
building resulted in different sample sizes and model 
performances (Table 1). Common among all models was the 
identification of the CCI as the most frequently selected and 
thus most important variable predicting six-months death, 
with increasing values predicting higher probability of death. 
Gender was consistently the second-most frequently selected 
variable. Regressing on the individual components of the CCI 
with the LASSO method showed that presence of a second 
solid tumor was the most important predictor, followed by 
various forms of heart disease (Figure 1). Replacing the CCI 
by these individual components in model building confirmed 
the strong relation between the presence of a second tumor 
and early death, but led to a worse model performance than 
with the full CCI (Table 1). Overall the accuracy of all models 
predicting six-months death was poor with maximum 
AUC=0.62. 
 
 
 
Conclusion: General patient characteristics together with 
comorbidity data, especially the history of a previous 
malignancy, can predict early death, however, prediction 
accuracy is insufficient to select patients to wait and see 
instead of offering SBRT as a curative treatment. 
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